Noah Rosen, MD: Evaluation of Cardiovascular Risks of Galcanezumab in Episodic, Chronic Migraine
The program director of neurology at the Zucker School of Medicine, Northwell Health, spoke about the great advances of the new CGRP medications available for the prevention of migraine.
By: Noah Rosen, MD
Published: August 02, 2019
"This has been a big year in the field of headache disorders with the release of a number of new medications for the prevention of migraine and with many more on the way."
At the 2019 American Academy of Neurology Annual Meeting, Noah Rosen, MD, program director of neurology at the Zucker School of Medicine, Northwell Health, sat with NeurologyLive to speak about the safety of the monoclonal antibodies toward CGRP for treatment of migraine.
Rosen and colleagues evaluated data related to cardiovascular events in patients with episodic or chronic migraine from 3, phase 3 double-blind, placebo-controlled studies of galcanezumab. In the study, researchers looked at hypertension, arrhythmia, and a variety of other risk factors including new-onset diabetes, and so forth, amongst the patient population that used galcanezumab.
There was no significant increase in blood pressure, pulse, and other adverse effects compared to placebo when looking at both the 120 mg and 240 mg doses of galcanezumab that were studied.
Oakes T, Kovacs R, Rosen N, et al. Evaluation of Cardiovascular Risks in Adult Patients with Episodic or Chronic Migraine Treated With Galcanezumab: Data From Three Phase 3, Randomized, Double-Blind, Placebo-Controlled Studies. Presented at: 2019 American Academy of Neurology 2019, Philadelphia, PA, May 4–10, 2019.